Uncategorized
STAT+: Dana-Farber CEO talks untangling from Mass General Brigham and building new cancer hospital
Benjamin Ebert became CEO of Dana-Farber Cancer Institute at an inflection point in late 2024, helming the organization in the midst of building a massive $1.6 billion cancer hospital, and winding down its partnership with Brigham and Women’s Hospital to instead pair up with Beth Israel Lahey Health.
The wheels of change were set in motion by his predecessor, Laurie Glimcher, who led Dana-Farber from 2016 to 2024. But Ebert, a medical oncologist who previously served as chair of the department of medical oncology at the institute for seven years, has no shortage of ideas and vision for Dana-Farber’s future. He recently detailed them to the Globe. This conversation has been edited for length and clarity.
You’ve embarked on this huge project set up by your predecessor. While things are coming together, it seems there’s still so much to do.
Benjamin Ebert became CEO of Dana-Farber Cancer Institute at an inflection point in late 2024, helming the organization in the midst of building a massive $1.6 billion cancer hospital, and winding down its partnership with Brigham and Women’s Hospital to instead pair up with Beth Israel Lahey Health.
The wheels of change were set in motion by his predecessor, Laurie Glimcher, who led Dana-Farber from 2016 to 2024. But Ebert, a medical oncologist who previously served as chair of the department of medical oncology at the institute for seven years, has no shortage of ideas and vision for Dana-Farber’s future. He recently detailed them to the Globe. This conversation has been edited for length and clarity.
You’ve embarked on this huge project set up by your predecessor. While things are coming together, it seems there’s still so much to do.
Uncategorized
Amgen shores up Tavneos’ FDA defense with Duke data analysis
Amgen shores up Tavneos’ FDA defense with Duke data analysis
After the FDA flagged patient deaths linked to Amgen’s rare disease drug Tavneos and called for its voluntary removal, the pharma recruited an independent data analysis from Duke researchers to help build the case for the drug’s continued market approval. Read More
Uncategorized
Chile offers new data on food warning label efficacy
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.
Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
So much news today that I didn’t have space to write an item about hot tubs as a breeding ground for Legionnaires’ disease. Here’s the CDC report, if you’re curious.
Uncategorized
Novartis’ $12B Avidity buy pays dividends with Phase 1/2 muscular dystrophy win
The RNA-based medicine is one of a handful of antibody-oligonucleotide conjugates that Novartis acquired last October when it took over neuromuscular-focused Avidity Biosciences.
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Uncategorized9 years agoAccording to Dior Couture, this taboo fashion accessory is back
-
Endpoints News3 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized9 years agoPhillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years agoUber and Lyft are finally available in all of New York State
-
Contributors9 years agoThe final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years agoSteph Curry finally got the contract he deserves from the Warriors
-
Uncategorized9 years agoThe old and New Edition cast comes together to perform